プログルミド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

プログルミド 価格

プログルミド 化学特性,用途語,生産方法

• 効能

  消化性潰瘍薬, ガストリン(コレシストキニンB)受容体拮抗薬

• 説明

  Proglumide (Milid) is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.
  Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.

• 化学的特性

  White Solid

• 使用

  Anticholinergic.

• 副作用

  An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs.
  Proglumide has also been shown to act as a δ-opioid agonist, which may contribute to its analgesic effects.

• 安全性プロファイル

  Moderately toxic by severalroutes. An experimental teratogen. When heated todecomposition it emits toxic fumes of NOx.

• 酵素阻害剤

  This anticholinergic agent (FWfree-acid = 334.42 g/mol; CAS 6620-60-6), also known as DL-4-benzamido-N,N-dipropylglutaramic acid and 4- (benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid, is a cholecystokinin receptor antagonist. Proglumide A also exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It finds use clinically as a therapy for gastrointestinal ulcers. Target(s): cholecystokinin receptor; gastrin receptor.

プログルミド 上流と下流の製品情報

プログルミド 生産企業

Global(178)Suppliers

6620-60-6, プログルミド キーワード